Telix Pharmaceuticals Ltd — AGM Information 2021

May 11, 2021

==> picture [143 x 79] intentionally omitted <==

CEO’s Address

Annual General Meeting

Melbourne (Australia) – 12[th] May 2021 . Telix Pharmaceuticals Limited (ASX:TLX, “Telix”, the “Company”) is pleased to provide the CEO’s Presentation to the Annual General Meeting of Shareholders being held today at 11.30am, at The Events Centre, Collins Square 727 Collins Street, Melbourne VIC 3008, Australia and by online presentation.

CEO’s Address

Good morning Shareholders and Colleagues,

I would like to begin by thanking Kevin McCann for his opening comments, and to acknowledge the tremendous support of the Board of Directors over the past twelve months. Leading a team that is spread out around the globe, facing daily personal and professional obstacles in the face of a pandemic, has been extremely challenging at times and it would not have been possible without the Board’s constant commitment to the welfare of the team.

When preparing our 2020 Annual Report, it became clear that we had a lot to tell Shareholders. We made good progress with our clinical development programs, despite a difficult execution environment. We still delivered almost 10,000 investigational and clinical trial doses across the Telix pipeline. Notwithstanding travel restrictions, we very successfully engaged in business development and commercial activity, a measure of Telix’s growing importance and influence as a life-sciences company. We grew the team and our capabilities significantly, while noting that this extraordinary level of team cooperation often took place between people that have never met in person yet manage share a passion and commitment to what Telix does. It hasn’t been easy, but it has been a very productive period.

We continue to grow the Company’s commercial prospects through research alliances with a number of global pharmaceutical companies, as well as regionally focused partnerships such as China Grand Pharma. We also continue to expand our pipeline, both through academic collaborations and research engagement, but also in-licensing and acquisition. As Telix gains prominence as a leading nuclear medicine company, we find ourselves becoming a soughtafter commercial partner for exciting new innovations in our field, both in terms of novel product opportunities but also expanding the clinical utility of our existing pipeline. An example of this was the acquisition of TheraPharm GmbH late last year, an opportunity that expands Telix’s product portfolio into new, high-value disease areas that go beyond our traditional oncology focus into hematology and rare diseases.

It has been a little over three years since we became a publicly traded company, with our IPO in November 2017. As a founder-led vision for a new healthcare firm, we are five years old. We are now focused on transitioning Telix to a “grown up” operating business that delivers on its clinical and commercial potential. As Kevin has outlined, a big part of this is building the risk management and governance framework to deliver on our development objectives. Over the past 12-18 months we have significantly upgraded our systems, processes and brought new and experienced talent into the business. As the founder CEO, it is extremely gratifying

Page 1

==> picture [143 x 79] intentionally omitted <==

to see the impact and moment of our growing global team and a greater degree of efficacy in our decision-making.

However, in terms of delivering a “grown-up” business, the biggest mind-shift we are undertaking is the transition to becoming a patient-centric firm. During the product development phase we care deeply about our engagement with patients as we run clinical trials and seek to demonstrate the potential clinical efficacy of our products. However, at the commercial phase of life, this patient-centricity must become fundamental to everything that we do and there is no corner of the business that is exempt from this evolution. It is my personal belief that in putting the patient first, that significant value creation for shareholders is a natural consequence.

Therefore, in terms of delivering this patient benefit, we have three major goals to deliver in 2021. There will, of course, be other accomplishments, data read-outs, commercial partnerships and so forth, but there are three main inflections that will define Telix for the next five years. We refer to these inflections as “Commence, Complete and Launch”. These are three words that are used relentlessly within the company and very much set the tempo of the business at this time.

Commence . This refers to commencing our phase III study of TLX591 for the treatment of prostate cancer. I am pleased to note that this study has now started here in Australia under the moniker of “ProstACT”, and will expand to US, European and possibly some Asian sites over the next 9 months or so. ProstACT is actually a small collection of studies, including the global phase III study, that is intended to demonstrate the utility of TLX591 in conjunction with standard of care, in patients with metastatic disease. Based on published data in around 200 patients and extensive consultation with regulators, we are confident of our pathway forward with ProstACT, even more so back of Novartis’ successful VISION trial. The market for prostate cancer therapy with targeted radionuclide approaches is a multibillion-dollar opportunity. It is a market that we believe we can own with a true “theranostic” approach – combining diagnostic imaging and therapy – with a product that we believe can deliver a significantly more durable treatment response for patients. As such, our goal over the next two years will be to demonstrate that we are a fast-follower with a best-in-class product.

Complete. One of the biggest commercial de-risks for Telix is a second approved product. When we launched Telix we knew that the commercial synergies between our prostate and renal cancer products would be significant. While we have competition in the prostate cancer theranostic arena, we believe we very little direct competition in the renal cancer space and so rapidly following lluccix® with a second urologic oncology product will be a key accomplishment for Telix in 2021. We expect the phase III ZIRCON trial of TLX250-CDx to complete enrolment around mid-year or early Q3, with a commitment to a recruitment update mid-July. COVID-19 has made this trial somewhat of a moving target, but current recruitment levels are very good across the 30-plus sites in the study, and we are dosing multiple patients every week. In parallel we are gearing up manufacturing and preparing to have key discussions with regulators, particularly the US Food and Drug Administration. Last year, the

FDA granted breakthrough designation for TLX250-CDx, a recognition of this product’s potential ability to address a clear unmet medical need, and this will potentially accelerate

Page 2

==> picture [143 x 79] intentionally omitted <==

product approval timelines for Telix’s second planned commercial product, subject to successful clinical outcomes and regulatory approval.

Launch . This goal is self-evident and one that is keenly watched by shareholders. Telix’s launch of lluccix® , will be an important measure of the Company’s future success, not just in terms of revenue generation but in terms of broader regulatory and commercial execution. We have a strong launch plan, aided by excellent partners in all our commercial jurisdictions, that share Telix’s passion and commitment to patient care. This graphic illustrates the bestestimates we have on timelines for approval in the 17 countries we are currently pursuing a marketing authorisation. We will certainly have a lot to keep shareholders informed about in the coming months.

While we do have competition, particularly in the US market, Illuccix® is not a “me too” product. Illuccix® represents the vanguard of prostate cancer imaging, the most extensive clinical experience, and a commercialisation roll-out plan that we believe will keep our competition playing catch-up. Telix has already delivered tens of thousands of doses to patients around the world, something that our competition can only dream of. Our use of the nuclear pharmacy model to roll-out Illuccix ® in the United States means that by the time we expect to get product approval, we will have over 100 nuclear pharmacies able to reach 95% of the US population, ready to go. Our approach is highly disruptive, and we are working closely with the FDA and other global regulatory authorities to make this important technology available to men with prostate cancer, as soon as possible.

Commence. Complete. Launch. It’s an exciting time for the Company and an exciting time to be a Telix shareholder. The most exciting part is that “commence, complete, launch” is not years away, it is months away.

Personally and professionally, it an enormous privilege to lead such a talented and capable team, and to have the possibility to deliver these important outcomes to patients and shareholders in the very near term. Of course, we cannot do this important work without you, our shareholders, and therefore on behalf of the Management team, I sincerely thank you for your support and encouragement.

==> picture [107 x 36] intentionally omitted <==

Dr. Christian P. Behrenbruch Managing Director and CEO Telix Pharmaceuticals Limited

Page 3

==> picture [143 x 79] intentionally omitted <==

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter @TelixPharma and LinkedIn.

Telix’s lead investigational product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA, and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA). Telix is also progressing marketing authorisation applications for Illuccix® in the European Union and Canada. None of Telix’s products have received a marketing authorisation in any jurisdiction.

Telix Corporate Contact Dr Christian Behrenbruch Telix Pharmaceuticals Limited CEO Email: chris@telixpharma.com

Telix Investor Relations

Dr. Stewart Holmstrom Telix Pharmaceuticals Limited Director of Corporate Communications Email: stewart.holmstrom@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “U.S. Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.

Page 4

==> picture [534 x 540] intentionally omitted <==

Annual General Meeting CEO’s Address

Dr. Christian Behrenbruch 12[th] of May 2021

Disclaimer

==> picture [126 x 76] intentionally omitted <==

The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (“Telix”) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.

This presentation may contain forward-looking statements which can be identified by the use of words such as “may”, “should”, “will”, “expect”, “anticipate”, “believe”, “estimate”, “intend”, “scheduled” or “continue” or similar expressions. Any forward-looking statements contained in this presentation are subject to significant risks, uncertainties, assumptions, contingencies and other factors (many of which are outside the control of, and unknown to Telix, and its directors, officers, employees, agents or associates), which may cause the actual results or performance to be materially different from any future result so performed, expressed or implied by such forward-looking statements.

There can be no assurance or guarantee that actual outcomes will not differ materially from these statements. The data and results pertaining to clinical subjects used in this presentation are illustrative of medical conditions and outcomes associated with potential applications of Telix’s product pipeline. Actual results from clinical trials may vary from those shown. None of the products or potential products described in this presentation have received a marketing authorisation in any jurisdiction.

Telix Pharmaceuticals Limited (ASX: TLX)

Grand Pharma Partnership

Collaborations

==> picture [290 x 197] intentionally omitted <==

----- Start of picture text -----

TheraPharm
----- End of picture text -----

==> picture [126 x 76] intentionally omitted <==

Seneffe, Belgium

2020 in 2020 in Review Review

3

2021: Commence, Complete, Launch

==> picture [126 x 76] intentionally omitted <==

==> picture [867 x 260] intentionally omitted <==

----- Start of picture text -----

Commence ProstACT Complete ZIRCON Launch Illuccix [®]
ZIRCON
Commence Phase III therapy trial Complete Phase III trial Regulatory approvals
Australia initially (H1) BLA [(1) ] preparation Commercial launch
EU and US (H2) Second commercial product First commercial revenue
----- End of picture text -----

Stakeholder Focus:

Become patient centric in everything we do. Become a revenue generating company.

1. Biologic license application.

Telix Pharmaceuticals Limited (ASX: TLX)

Illuccix® Timelines (Estimated)

==> picture [126 x 76] intentionally omitted <==

==> picture [867 x 413] intentionally omitted <==

Planned US Illuccix® Roll-Out

==> picture [126 x 76] intentionally omitted <==

Illuccix® (Kit for the preparation of 68Ga-PSMA-11) is an investigational product and has not attained a marketing authorisation in any jurisdiction, including the United States. Product launch in the United States is subject to FDA approval of a New Drug Application (NDA)

• Superior network coverage at launch

• On-demand pharmacy-based production with a high yield product • Customer and patient scheduling Telix flexibility Partners Competition Puerto Rico, Alaska, Hawaii not shown

Telix Pharmaceuticals Limited (ASX: TLX)

==> picture [126 x 76] intentionally omitted <==

telixpharma.com

==> picture [960 x 63] intentionally omitted <==